Research programme: wound healing agents - ChemokineAlternative Names: CTC-0422; CTCE 0422
Latest Information Update: 24 Jul 2007
At a glance
- Originator Chemokine Therapeutics
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Wounds
Most Recent Events
- 24 Jul 2007 CTCE 0422 is still in preclinical development for wound healing in Canada
- 07 Mar 2006 Preclinical trials in Wounds in Canada (unspecified route)